Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study.

IF 3.2 3区 医学 Q2 ONCOLOGY Clinical oncology Pub Date : 2024-08-19 DOI:10.1016/j.clon.2024.08.008
K Fife, C Pearson, C S Knott, A Greaves, G D Stewart
{"title":"Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study.","authors":"K Fife, C Pearson, C S Knott, A Greaves, G D Stewart","doi":"10.1016/j.clon.2024.08.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To establish whether there are geographic differences in treatments and outcomes for patients with kidney cancer (KC) in England which could potentially be improved by the creation of national guidelines.</p><p><strong>Materials and methods: </strong>A multidisciplinary group convened by the charity Kidney Cancer UK developed Quality Performance Indicators (QPIs) for the treatment of KC. Adherence to these QPIs was reported for all patients with a histological diagnosis of KC diagnosed in England between 2017 and 2018. Utilising data extracted from national datasets, logistic and linear probability models were used to estimate geographic variation in the delivery of surgery and systemic anti-cancer therapy at Cancer Alliance and NHS trust levels. Results were adjusted for a priori confounders, including age at diagnosis, area deprivation of residence, and Charlson Comorbidity Index. Differences in overall survival are reported.</p><p><strong>Results: </strong>The cohort comprised 18,640 tumours in 18,421 patients. Of tumours diagnosed, median patient age was 68 (interquartile range 58-77) years and 63.4% were in males. When stratified by Cancer Alliance, the proportions of T1a/T1b/N0/M0 KC that had radical nephrectomy (RN), nephron sparing surgery or ablation ranged from 53.3% (95% CI [48.7, 57.8]) to 80.3% (95% CI [73.0, 86.0]). For stage T1b-3 cancers, the proportion that received RN ranged from 65.6% (95% CI [60.3, 70.5]) to 77.3% (95% CI [72.1, 81.7]). Patients with M0 (n = 12,365) and M1 KC (n = 3312) at diagnosis had 24-month survival of 87.5% and 25.1%, respectively. Of patients diagnosed with M1 KC, 50.3% received systemic anti-cancer therapy, ranging from 39.7% (95% CI [33.7, 46.1]) to 70.7% (95% CI [59.6, 79.8]) between Cancer Alliances. The six-month survival of these patients was 77.4% compared to 27.6% for those that did not receive SACT.</p><p><strong>Conclusion: </strong>These major geographical differences in surgical and systemic therapy practice have led to national guideline development.</p>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clon.2024.08.008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: To establish whether there are geographic differences in treatments and outcomes for patients with kidney cancer (KC) in England which could potentially be improved by the creation of national guidelines.

Materials and methods: A multidisciplinary group convened by the charity Kidney Cancer UK developed Quality Performance Indicators (QPIs) for the treatment of KC. Adherence to these QPIs was reported for all patients with a histological diagnosis of KC diagnosed in England between 2017 and 2018. Utilising data extracted from national datasets, logistic and linear probability models were used to estimate geographic variation in the delivery of surgery and systemic anti-cancer therapy at Cancer Alliance and NHS trust levels. Results were adjusted for a priori confounders, including age at diagnosis, area deprivation of residence, and Charlson Comorbidity Index. Differences in overall survival are reported.

Results: The cohort comprised 18,640 tumours in 18,421 patients. Of tumours diagnosed, median patient age was 68 (interquartile range 58-77) years and 63.4% were in males. When stratified by Cancer Alliance, the proportions of T1a/T1b/N0/M0 KC that had radical nephrectomy (RN), nephron sparing surgery or ablation ranged from 53.3% (95% CI [48.7, 57.8]) to 80.3% (95% CI [73.0, 86.0]). For stage T1b-3 cancers, the proportion that received RN ranged from 65.6% (95% CI [60.3, 70.5]) to 77.3% (95% CI [72.1, 81.7]). Patients with M0 (n = 12,365) and M1 KC (n = 3312) at diagnosis had 24-month survival of 87.5% and 25.1%, respectively. Of patients diagnosed with M1 KC, 50.3% received systemic anti-cancer therapy, ranging from 39.7% (95% CI [33.7, 46.1]) to 70.7% (95% CI [59.6, 79.8]) between Cancer Alliances. The six-month survival of these patients was 77.4% compared to 27.6% for those that did not receive SACT.

Conclusion: These major geographical differences in surgical and systemic therapy practice have led to national guideline development.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
英国肾癌治疗和存活率的差异:全国队列研究结果
目的:确定英国肾癌(KC)患者的治疗方法和结果是否存在地域差异,并通过制定国家指南加以改进:由英国肾癌慈善机构召集的一个多学科小组制定了肾癌治疗的质量绩效指标(QPIs)。对2017年至2018年期间在英格兰确诊的所有组织学诊断为KC的患者遵守这些QPIs的情况进行了报告。利用从国家数据集中提取的数据,采用逻辑和线性概率模型来估算癌症联盟和 NHS 信托基金各级手术和全身抗癌治疗实施的地域差异。结果已根据先验混杂因素(包括诊断时的年龄、居住地贫困程度和夏尔森综合指数)进行调整。报告了总生存率的差异:研究对象包括18,421名患者的18,640个肿瘤。在确诊的肿瘤患者中,中位年龄为68岁(四分位数间距为58-77岁),63.4%为男性。根据癌症联盟进行分层后,T1a/T1b/N0/M0 KC 中接受根治性肾切除术 (RN)、肾小球保留手术或消融术的比例从 53.3% (95% CI [48.7, 57.8])到 80.3% (95% CI [73.0, 86.0])不等。对于T1b-3期癌症,接受RN治疗的比例从65.6%(95% CI [60.3,70.5])到77.3%(95% CI [72.1,81.7])不等。确诊时为M0(n = 12365)和M1 KC(n = 3312)的患者的24个月生存率分别为87.5%和25.1%。在确诊为M1 KC的患者中,50.3%接受了全身抗癌治疗,癌症联盟之间的比例从39.7%(95% CI [33.7,46.1])到70.7%(95% CI [59.6,79.8])不等。这些患者的 6 个月生存率为 77.4%,而未接受 SACT 的患者的 6 个月生存率为 27.6%:结论:手术和系统治疗实践中存在的这些重大地域差异促成了国家指南的制定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical oncology
Clinical oncology 医学-肿瘤学
CiteScore
5.20
自引率
8.80%
发文量
332
审稿时长
40 days
期刊介绍: Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.
期刊最新文献
PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis. "If You're Talking, I Think You're Muted": Follow-up Analysis of Weekly Peer Review Discussion and Plan Changes After Transitioning From Virtual to In-Person Format. The Current use of Adaptive Strategies for External Beam Radiotherapy in Cervical Cancer: A Systematic Review. The Use of Artificial Intelligence Technologies in Cancer Care. Response Letter to Laurelli et al. Letter to the Editor Regarding Enhancing Telemedicine to Improve Global Radiotherapy Access.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1